newsfilter
← Latest News
Business Wire·

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

RP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first